Roundtables: Discussing Regulatory Challenges Across Different Stages of Dry AMD Therapeutics Development

Time: 4:15 pm
day: Day Two


Some of the biggest challenges when developing drug for dry AMD is understanding the regulatory landscape for all stages of drug development. This session facilitates discussions on a range of regulatory checkpoints including:

  • Pre-IND
  • Endpoint Designation
  • Recruiting & Phase I
  • Phase II & Phase III